BRAF p.Val600Glu突变在腺瘤样牙源性肿瘤中未检出
腺瘤样牙源性肿瘤(AOT)中KRAS codon 12突变占70%,其余30%发病机制不明。本研究对29例AOT样本(21例KRAS codon 12突变阳性、8例野生型)采用等位特异性qPCR和/或Sanger测序检测BRAF p.Val600Glu,均未检出。4例样本还进行了KRAS codon 146测序,均为野生型。结果表明BRAF p.Val600Glu不是AOT的分子特征,且不支持BRAF与KRAS突变共现。
要点
- BRAF p.Val600Glu在29例AOT中均未检出,不支持其作为AOT诊断依据。
- KRAS codon 12突变在AOT中占主导,BRAF突变与KRAS突变互斥。
- KRAS codon 12野生型病例中KRAS codon 146也为野生型。
核心结论
- BRAF p.Val600Glu不是AOT的分子特征,且BRAF与KRAS突变互斥。
研究设计与样本
- 29例AOT样本,包括21例KRAS codon 12突变阳性病例和8例野生型病例,检测BRAF p.Val600Glu。
- 使用等位特异性qPCR和/或Sanger测序检测BRAF p.Val600Glu。
- 对4例样本进行KRAS codon 146的Sanger测序。
主要发现
- 29例AOT中均未检出BRAF p.Val600Glu,无论单独或与KRAS突变共存。
- 所有KRAS codon 12野生型病例的KRAS codon 146均为野生型。
关键数值与推荐
- KRAS p.Gly12Val或p.Gly12Arg突变在AOT中占70%。
- BRAF p.Val600Glu在29例AOT中检出率为0。
临床怎么用
- BRAF p.Val600Glu检测阴性支持AOT诊断,尤其在疑难病例中。
- AOT分子检测应优先关注KRAS codon 12突变。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The adenomatoid odontogenic tumor (AOT) is a benign, encapsulated odontogenic tumor characterized by slow growth and indolent behavior. AOT shows mitogen-activated protein kinase/ERK pathway activation, and KRAS p.Gly12Val or p.Gly12Arg mutations occur in 70% of cases. The molecular events underlying the pathogenesis of the other 30% of cases remain unclear. The BRAF p.Val600Glu mutation was reported by a single study in 2 AOT cases, 1 of which also harbored KRAS p.Gly12Val. Given that BRAF p.Val600Glu has not been previously detected in AOT and that BRAF and KRAS mutations are mutually exclusive, we aimed to assess BRAF p.Val600Glu irrespective of KRAS mutational status to explore the potential involvement of BRAF mutations in AOT pathogenesis and the co-occurrence of BRAF and KRAS mutations. Whereas KRAS codon 13 and 61 hotspot mutations have not been previously detected in AOT, KRAS codon 146 hotspot mutations have been investigated in a few AOT cases to date. Therefore, we further sequenced KRAS codon 146 in KRAS codon 12 wild-type cases. A total of 29 AOT samples, including 21 KRAS codon 12 mutation-positive cases and 8 wild-type cases, were evaluated for the BRAF p.Val600Glu pathogenic mutation using allele-specific qPCR and/or Sanger sequencing. In addition, KRAS codon 146 was Sanger sequenced in 4 out of 29 samples. BRAF p.Val600Glu was not detected in any of the 29 AOT cases evaluated, either alone or as a comutation with KRAS mutations. All codon 12 wild-type cases were wild-type for KRAS codon 146 mutations. These findings reinforce that KRAS codon 12 mutant alleles predominate in the context of AOT tumorigenesis, whereas BRAF p.Val600Glu does not constitute a molecular feature of this tumor and the presence of the BRAF mutation does not support the diagnosis of AOT in challenging cases. In addition, the results further strengthen the notion that BRAF and KRAS mutations are mutually exclusive events.
引用
- Gonçalves J, Coura BP, Bernardes VF, et al. BRAF p.Val600Glu Mutations Are Not Detected in Adenomatoid Odontogenic Tumors. Mod Pathol. 2025. PMID: 41207629. doi:10.1016/j.modpat.2025.100933
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。